Manufacturing clinical‐grade human induced pluripotent stem cell‐derived beta cells for diabetes treatment

The unlimited proliferative capacity of human pluripotent stem cells (hPSCs) fortifies it as one of the most attractive sources for cell therapy application in diabetes. In the past two decades, vast research efforts have been invested in developing strategies to differentiate hPSCs into clinically...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Lay Shuen, Chen, Juin Ting, Lim, Lillian Yuxian, Teo, Adrian Kee Keong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357357/
https://www.ncbi.nlm.nih.gov/pubmed/35474596
http://dx.doi.org/10.1111/cpr.13232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357357/
https://www.ncbi.nlm.nih.gov/pubmed/35474596
http://dx.doi.org/10.1111/cpr.13232

Ejemplares similares